A National Registry on Chinese Patients With Cystic Fibrosis

Recruiting

• Conditions: Pulmonary Function

• Registration Number: NCT05289245
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-03
• Study First Submitted: 2022-03-13
• Study First Submitted QC: 2022-03-13
• Last Update Submitted: 2022-03-13
• Study First Posted: 2022-03-21
• Last Update Posted: 2022-03-21
• Study Start: 2022-04-01
• Primary Completion: 2032-10-01
• Study Completion: 2032-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.

Exclusion Criteria

Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.	10 years	Spirometry will be evaluated at baseline and through study completion, an average of 3 years.

Trial Locations

Locations (1)

Peking Union Medical College Hospital; 🇨🇳 Beijing, Beijing, China